Skip to main content
Premium Trial:

Request an Annual Quote

GenoSpectra Lands $20M in Second-Round Funding

SAN FRANCISCO, Dec. 19 - Microarray start-up GenoSpectra received $20 million in a second round of private financing, the company said Wednesday.


The investment, lead by Seattle, Wash.-based Frazier Healthcare Ventures, included Novartis BioVentures, HBM BioVentures, and the BioMedical Sciences Investment Fund of the Singapore Economic Development Board.


GenoSpectra, based in Fremont, Calif., is developing high throughput drug screening and high-density DNA and protein microarrays based on fiber optics technology, which the company said allows the production of relatively inexpensive arrays with massive parallel processing.


GenoSpectra was founded in April 2000 and received $5 million in Series A financing in October 2000.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.